Literature DB >> 19891011

Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C.

Juan-Ramón Larrubia1, Selma Benito-Martínez, Joaquín Miquel, Miryam Calvino, Eduardo Sanz-de-Villalobos, Trinidad Parra-Cid.   

Abstract

Hepatitis C virus (HCV)-specific CD8(+) T cells play an important role in the resolution of HCV infection. Nevertheless, during chronic hepatitis C these cells lack their effector functions and fail to control the virus. HCV has developed several mechanisms to escape immune control. One of these strategies is the up-regulation of negative co-stimulatory molecules such us programmed death-1 (PD-1). This molecule is up-regulated on intrahepatic and peripheral HCV-specific cytotoxic T cells during acute and chronic phases of the disease, whereas PD-1 expression is low in resolved infection. PD-1 expressing HCV-specific CD8(+) T cells are exhausted with impairment of several effector mechanisms, such as: type-1 cytokine production, expansion ability after antigen encounter and cytotoxic ability. However, PD-1 associated exhaustion can be restored by blocking the interaction between PD-1 and its ligand (PD-L1). After this blockade, HCV-specific CD8(+) T cells reacquire their functionality. Nevertheless, functional restoration depends on PD-1 expression level. High PD-1-expressing intrahepatic HCV-specific CD8(+) T cells do not restore their effector abilities after PD-1/PD-L1 blockade. The mechanisms by which HCV is able to induce PD-1 up-regulation to escape immune control are unknown. Persistent TCR stimulation by a high level of HCV antigens could favour early PD-1 induction, but the interaction between HCV core protein and gC1q receptor could also participate in this process. The PD-1/PD-L1 pathway modulation could be a therapeutic strategy, in conjunction with the regulation of others co-stimulatory pathways, in order to restore immune response against HCV to succeed in clearing the infection. 2009 The WJG Press and Baishideng. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19891011      PMCID: PMC2773891          DOI: 10.3748/wjg.15.5129

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  97 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

Review 2.  Replication of hepatitis C virus.

Authors:  R Bartenschlager; V Lohmann
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

Review 3.  Local control of the immune response in the liver.

Authors:  P A Knolle; G Gerken
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

4.  Vaccination to treat persistent viral infection.

Authors:  M G von Herrath; D P Berger; D Homann; T Tishon; A Sette; M B Oldstone
Journal:  Virology       Date:  2000-03-15       Impact factor: 3.616

5.  Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

Authors:  N H Grüner; T J Gerlach; M C Jung; H M Diepolder; C A Schirren; W W Schraut; R Hoffmann; R Zachoval; T Santantonio; M Cucchiarini; A Cerny; G R Pape
Journal:  J Infect Dis       Date:  2000-05-05       Impact factor: 5.226

6.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

7.  Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation.

Authors:  D J Kittlesen; K A Chianese-Bullock; Z Q Yao; T J Braciale; Y S Hahn
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

8.  Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell development in acute self-limited hepatitis B patients.

Authors:  Zheng Zhang; Bo Jin; Ji-Yuan Zhang; Bin Xu; Huifen Wang; Ming Shi; E John Wherry; George K K Lau; Fu-Sheng Wang
Journal:  J Hepatol       Date:  2009-03-29       Impact factor: 25.083

9.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  Enhancing SIV-specific immunity in vivo by PD-1 blockade.

Authors:  Vijayakumar Velu; Kehmia Titanji; Baogong Zhu; Sajid Husain; Annette Pladevega; Lilin Lai; Thomas H Vanderford; Lakshmi Chennareddi; Guido Silvestri; Gordon J Freeman; Rafi Ahmed; Rama Rao Amara
Journal:  Nature       Date:  2008-12-10       Impact factor: 49.962

View more
  11 in total

1.  An intermediate dose of LCMV clone 13 causes prolonged morbidity that is maintained by CD4+ T cells.

Authors:  Andrew Stamm; Laura Valentine; Rashaun Potts; Mary Premenko-Lanier
Journal:  Virology       Date:  2012-02-04       Impact factor: 3.616

2.  Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2015-04-14       Impact factor: 4.345

3.  Ineffective CD8(+) T-cell immunity to adeno-associated virus can result in prolonged liver injury and fibrogenesis.

Authors:  Jessica Spahn; Robert H Pierce; Ian N Crispe
Journal:  Am J Pathol       Date:  2011-09-15       Impact factor: 4.307

Review 4.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

5.  T cells increase before zoster and PD-1 expression increases at the time of zoster in immunosuppressed nonhuman primates latently infected with simian varicella virus.

Authors:  Stephanie F James; Vicki Traina-Dorge; Eileen Deharo; Mary Wellish; Brent E Palmer; Don Gilden; Ravi Mahalingam
Journal:  J Neurovirol       Date:  2014-02-19       Impact factor: 2.643

Review 6.  Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.

Authors:  Elia Moreno-Cubero; Juan-Ramón Larrubia
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

7.  Lack of significant elevation of myeloid-derived suppressor cells in peripheral blood of chronically hepatitis C virus-infected individuals.

Authors:  Julia Nonnenmann; Renate Stirner; Julia Roider; Maria C Jung; Kathrin Schrödl; Johannes R Bogner; Rika Draenert
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

8.  Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1.

Authors:  Noelle A Hutchins; Fei Wang; Yvonne Wang; Chun-Shiang Chung; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2013-06-13       Impact factor: 4.962

Review 9.  Adaptive immune response during hepatitis C virus infection.

Authors:  Juan Ramón Larrubia; Elia Moreno-Cubero; Megha Uttam Lokhande; Silvia García-Garzón; Alicia Lázaro; Joaquín Miquel; Cristian Perna; Eduardo Sanz-de-Villalobos
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 10.  The Role of PD-1 in Acute and Chronic Infection.

Authors:  Jil M Jubel; Zachary R Barbati; Christof Burger; Dieter C Wirtz; Frank A Schildberg
Journal:  Front Immunol       Date:  2020-03-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.